Healx Logo

Company

Investors

Invest in the future of drug discovery

We’re proud to be supported by some of the world’s leading investors who have a strong track record of working with successful, high-growth companies.

We’ve raised over $70 million to date and are grateful for the continued support of our partners – from seed round to Series B and beyond.

We are always keen to hear from companies who share our vision to use AI to accelerate the discovery and development of rare disease treatments at scale. Please get in touch to explore ways of working together.

Contact us
Vector
Vector Irina Haivas

We believe that the new paradigm in drug discovery will emerge at the intersection of technology, data, and biology, and we’re confident that Healx’s team is paving the way to a new gold standard in rare disease treatment discovery.

Irina Haivas
Partner at Atomico and Board Member of Healx
Vector Suranga Chandratillake

The future of medicine will focus on what is different about everyone, personalising treatment and taking the individual into context. Healx’s Healnet platform, at the forefront of this shift, is already delivering value and Balderton is excited to have the opportunity to be part of the company’s journey.

Suranga Chandratillake
Partner at Balderton Capital and Board Member of Healx
Vector Trina Van Pelt

AI coupled with compute can disrupt and dramatically speed the drug discovery process, and Healx owns the most comprehensive knowledge graph of rare diseases. We’re excited to support this experienced leadership team and provide Intel technology to optimize deep learning workloads, improve performance and lower costs.

Trina Van Pelt
Vice President and Senior Managing Director at Intel Capital
Vector Jonathan Milner

It’s a pleasure to have been part of Healx since the very beginning. The way they’ve scaled the team, the tech and the number of rare disease projects worked on over the years has been astonishing to watch. If ever proof was needed of the power of technology for societal good - this is it.

Jonathan Milner
Angel Investor and Board Member of Healx
Vector Dr Ronjon Nag

The way Healx blends the latest AI technology with exceptional drug discovery expertise and patient insights has not only disrupted the traditional approach to drug discovery - it’s the secret ingredient to their success to-date in quickly and effectively finding potential treatments for rare diseases.

Dr Ronjon Nag
President at R42 Group and Advisory Board Member of Healx

Our technology

Our AI leverages its unique combination of algorithms to predict and de-risk novel connections in biomedical data, and move the most promising ones towards the clinic.

Find us on social media